Muscarinic receptor agonists in Alzheimer's disease more than just symptomatic treatment?

CNS Drugs

Volumn 12, Issue 3, 1999, Pages 197-214

  Fisher, Abraham ^a  

^a ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACECLIDINE; ACETYLCHOLINE; ARECOLINE; CARBACHOL; CEVIMELINE; DONEPEZIL; GALANTAMINE; MILAMELINE; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR; MUSCARONE; PILOCARPINE; QUINUCLIDINE; RIVASTIGMINE; SABCOMELINE; TACRINE; TALSACLIDINE; XANOMELINE;

ALZHEIMER DISEASE; CHEMICAL MODIFICATION; DIAPHORESIS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; REVIEW; SALIVATION; SIDE EFFECT; SYNCOPE;

EID: 0032847552     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199912030-00004     Document Type: Review

References (123)

1. Court JA, Periv EK. Dementia: the neurochemical basis of putative transmitter orientated therapy. Pharmac Ther 1991; 52: 423-43
2. Fisher A. Barak D. Progress and perspectives in new muscarinic agonists. Drug News Perspectives 1994; 7: 453-64
3. Simonson W. Promising agents for treating Alzheimer's disease. Am J Health Cvst Pharm 1998; 55: S11-S16
4. Spencer CM, Noble S. Rivastigmine: a review of its use in Alzheimer's disease. Drugs Aging 1998; 13: 391-411
5. Cummings JL, Vinters HV, Cole GM, et al. Etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology 1998; 51: S2-S17
6. Giacobini E. From molecular structure to Alzheimer therapy. Jap J Pharmacol 1997; 74: 225-41
7. Pavia J, de Ceballos ML, de la Cuesta FS. Alzheimer's disease: relationship between muscarinic cholinergic receptors, beta-amyloid and tau proteins. Fundam Clin Pharmacol 1998; 12: 473-81
8. Avery EE, Baker LD. Asthana S, et al. Potential role of muscarinic agonists in Alzheimer's disease. Drugs Aging 1997: 11: 450-9
9. Eglen RM, Hegde SS. Muscarinic receptor subtypes: pharmacology and therapeutic potential. DN & P 1997; 10: 462-9
10. Fisher A. Muscarinic agonists for the treatment of Alzheimer's disease: progress and perspectives. Exp Opin Invest Drugs 1997; 6: 1395-411
11. Wulfert E. Treatment development strategies for Alzheimer's disease. CNS Drug Rev 1996; 2: 238-55
12. Emmerling MR, Schwarz RD, Spiegel K, et al. New perspectives on developing muscarinic agonists for treating Alzheimer's disease [database]. Alzheimer's Dis 1997; 2 (4)
13. Svensson AL, Alafuzoff I. Nordberg A. Characterization of muscarinic receptor subtypes in Alzheimer and control brain cortices by selective muscarinic antagonists. Brain Res 1992; 596: 142-8
14. Fisher A. editor. Muscarinic agonists and Alzheimer's disease. Austin (TX): RG Landes Company, Medical Intelligence Unit, 1996
15. Harrison PJ, Barton AJL, McDonald B, et al. Alzheimer's disease: specific increases in a G-protein subunit (Gsα) mRNA in hippocampal and cortical neurons. Mol Brain Res 1991; 10: 71-81
16. Gurwitz D, Haring R, Heldman E, et al. Discrete activation of transduction pathways associated with acetylcholine M1 receptor by several muscarinic ligands. Eur J Pharmacol (Mol Pharmacol) 1994; 267: 21-31
17. Nitsch RN, Slack BE, Wartman RJ, et al. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 1992; 258: 304-7
18. Bowen DM, Francis PT, Chessell IP, et al. Neurotransmission the link integrating Alzheimer research? TINS 1994; 17: 149-50
19. Buxbaum JD, Oishi M, Chen HJ, et al. Cholinergic agonists and interleukin I regulate processing and secretion of the Alzheimer β/A4 amyloid protein precursor. Proc Natl Acad Sci U S A 1992; 89: 10075-8
20. Lahiri DK, Nall C, Farlow MR. The cholinergic agonist carbachol reduces intercellular β-amyloid precursor protein in PC12 and C6 cells. Biochem Int 1992; 28: 853-60
21. Haring R, Gurwitz D, Barg J, et al. Amyloid precursor protein secretion via muscarinic receptors: reduced desensitization using the M1-selective agonist AF102B. Biochem Biophys Res Comm 1994; 203: 652-8
22. Eckols K, Bymaster FP, Mitch CH, et al. The muscarinic M1 agonist xanomeline increases soluble amyloid precursor protein release from CHO M1 cells. Life Sci 1995; 57: 1183-90
23. Haring H, Fisher A, Marciano D, et al. Mitogen-activated kinase-dependent and protein kinase C-dependent pathways link the M1 muscarinic receptor to β-amyloid precursor protein secretion. J Neurochem 1998; 71: 2094-103
24. Hung AY, Haass C, Nitsch RT, et al. Activation of protein kinase C inhibits cellular production of the amyloid β-protein. J Biolog Chem 1993; 268: 22959-62
25. Wolf BA, Wertkin AM, Jolly YC, et al. Muscarinic regulation of Alzheimer's disease amyloid precursor protein secretion and amyloid beta-protein production in human neuronal NT2N cells. J Biol Chem 1995; 270: 4916-22
26. Checler F. Processing of the β-Amyloid precursor protein and its regulation in Alzheimer's disease. J Neurochem 1995; 65: 1431-44
27. Pinkas-Kramarski R, Stein R, Lindenboim L, et al. Growth factor-like effects mediated by muscarinic receptors in PC12M1 cells. J Neurochem 1992; 59: 2158-66
28. Gurwitz D, Haring R, Pinkas-Kramarski R, et al. NGF-dependent neurotrophic-like effects of AF102B, an M1 muscarinic agonist, in PC12M1 cells. NeuroReport 1995; 6: 485-8
29. Mount HTJ, Dreyfus CF, Black IB, et al. Muscarinic stimulation promotes cultured Purkinje cell survival: a role for acetylcholine in cerebellar development? J Neurochem 1994; 63: 2065-73
30. Alberch J, Gurwitz D, Fisher A, et al. Novel muscarinic M1 receptor agonists promote survival of CNS neurons in primary cell culture. Soc Neurosci Abstr 1995; 21: 2040
31. Haring R, Gurwitz D, Barg J, et al. NGF promotes amyloid protein secretion via muscarinic receptor activation. Biochem Biophys Res Comm 1995; 213: 15-23
32. Sadot E, Gurwitz D, Barg J, et al. Activation of M1-muscarinic acetylcholine receptor regulates tau phosphorylation in transfected PC12 cells. J Neurochem 1996; 66; 877-80
33. Forlenza O, Spink J, Oleson O, et al. Muscarinic agonists reduce tau phosphorylation in transfected cells and in neurons [abstract]. Neurobiol Aging 1998; 19: S218
34. Genis I, Fisher A, Michaelson DM. Site-specific dephosphorylation of tau of apolipoprotein E-deficient and control mice by M1 muscarinic agonist treatment. J Neurochem 1999; 12 (1): 206-13
35. Lindenboim L, Pinkas-Kramarski R, Sokolovsky M, et al. Activation of muscarinic receptors inhibits apoptosis in PC12M1 cells. J Neurochem 1995; 64: 2491-9
36. von der Kammer H, Mayhaus M, Albrecht C, et al. Muscarinic acetylcholine receptors activate expression of the Egr gene family of transcription factors. J Biolog Chem 1998; 273 (23): 14538-44
37. Nitsch RM, Rossner S, Albrecht C, et al. Muscarinic acetylcholine receptors activate the acetylcholinesterase gene promoter. J Physiol (Paris) 1998; 92 (3-4): 257-64
38. Schwarz RD. Muscarinic receptor agonists under development for the treatment of Alzheimer's disease. Alzheimer's Dis 1997; 2: 459-65
39. Parnetti L, Senin U, Mecocci P. Cognitive enhancement therapy for Alzheimer's disease. Drugs 1997; 53: 752-68
40. Eglen RM, Watson N. Selective muscarinic receptor agonists and antagonists. Pharmacol Toxicol 1996; 78: 59-8
41. Moltzen EK, Bjornholm B. Medicinal chemistry of muscarinic agonists: developments since 1990. Drugs Future 1995; 20: 37-54
42. Hulme EC, Birdsall NJM, Buckley NJ. Muscarinic receptor subtypes. Ann Rev Pharmacol Toxicol 1990; 30: 633-73
43. Caulfield MP, Birdsall NJM. International Union of Pharmacology. XVII. Classification of Muscarinic Acetylcholine Receptors 1998; 50 (2): 279-90
44. Bymaster EP, Shannon HE, Mitch CH, et al. Xanomeline: preclinical and clinical pharmacology of an M1 muscarinic agonist. In: Fisher A, editor. Muscarinic agonists and Alzheimer's disease. Austin (TX): RG Landes Company, Medical Intelligence Unit. 1996: 155-84
45. Falcone JF, Bymaster FP, Butler T, et al. Determination of the intrinsic functional muscarinic activity of xanomeline. Subtypes of muscarinic receptors. 8th International Symposium; 1998 Aug 25-29; Danvers (MA), USA
46. Bymaster FP, Whitesitt CA, Shannon HE, et al. Xanomeline: a selective muscarinic agonist for the treatment of Alzheimer's disease. Drug Develop Res 1997; 40: 158-70
47. Freedman SB, Patel S, Harley EA, et al. L-687,306: a functionally selective and potent muscarinic M1 receptor agonist. Eur J Pharmacol 1992; 215: 135-6
48. Freedman SB, Dawson GR, Iversen LL, et al. The design of novel muscarinic partial agonists that have functional selectivity in pharmacological preparations in vitro and reduced side-effect profile in vitro and reduced side-effect profile in vivo. Life Sci 1993; 52: 489-95
49. Meier E, Frederiksen K, Nielsen M, et al. Pharmacological in vitro characterization of the arecoline bioisostere, Lu 25-109-T, a muscarinic compound with M1-agonistic and M2/M3-antagonistic properties. Drug Develop Res 1997; 40: 1-16
50. Muller D, Wiegmann H, Langer U, et al. Lu 25-109, a combined ml agonist and m2 antagonist, modulates regulated processing of the amyloid precursor protein of Alzheimer's disease. J Neural Transm 1998; 105: 1029-43
51. Heisterberg J, Forrest M. Lu 25-109 - a new muscarinic agent. Neurobiol Aging 1996; Suppl. 17: S139
52. Sramek JJ, Forrest M, Mengel H, et al. A bridging study of LU 25-109 in patients with probable Alzheimer's disease. Life Sci 1998; 62: 195-202
53. Forest's M1 agonist in Alzheimer's disease fails. SCRIP 1998 Aug 26: 16
54. Davis R, Raby C, Callahan MJ, et al. Subtype selective muscarinic agonists: potential therapeutic agents for Alzheimer's disease. Prog Brain Res 1993; 98: 439-45
55. Tecle H, Lauffer DJ, Mirzadegan T, et al. Synthesis and SAR of bulky l-azabicyclo[2.2.1]-3-one oximes as muscarinic receptor subtype selective agonists. Life Sci 1993; 52: 505-11
56. Jaen J, Barrett S, Brann M, et al. In vitro and in vivo evaluation of the subtype-selective muscarinic agonist PD 151832. Life Sci 1995; 56: 845-52
57. Messer WS Jr, Abuh YF, Ryan K, et al. Tetrahydropyrimidine derivatives display functional selectivity for M1 muscarinic receptors in brain. Drug Develop Res 1997; 40: 171-84
58. Shapiro G, Floersheim P, Boelsterli J, et al. Muscarinic activity of the thiolactone, lactam, lactol and thio analogues of pilocarpine and a hypothetical model for the binding of agonists to the M1 receptors. J Med Chem 1992; 35: 15-27
59. Enz A, Boddeke H, Sauter A, et al. SDZ ENS 163 a novel pilocarpine like drug: pharmacological in vitro and in vivo profile. Life Sci 1993; 52 (5-6): 513-20
60. Wanibuchi F, Konishi T, Harada M, et al. Pharmacological studies on novel muscarinic agonists, l-oxa-8-azaspiro[4.5]decane derivatives, YM796 and YM954. Eur J Pharmacol 1990; 187: 479-86
61. Wu ES, Kover A. Spiro-ixoazolidine derivatives as cholinergic agents. US patent 5,073,560. 1991 Dec 17
62. Sabb AL, Stein RP, Vogel RL, et al. WAY-131256 is an orally active, efficacious, and in-vivo functionally selective M1 agonist. Drug Develop Res 1997; 40: 185-92
63. Loudon JM, Bromidge SM, Brown F, et al. SB 202026: a novel muscarinic partial agonist with functional selectivity for M1 receptors. J Pharmacol Exp Ther 1997; 283: 1059-68
64. Kumar R, Orgogozo J. Efficacy and safety of SB 202026 as a symptomatic treatment for Alzheimer's disease. In: Iqbal K, Winblad B, Nishimura T, et al., editors. Alzheimer's disease: biology, diagnosis and therapeutics. New York (NY): John Wiley and Sons, 1997: 677-85
65. Ensinger HA, Bechtel WD, Birke FW, et al. WAL 2014 FU (Talsaclidine): a preferentially neuron activating muscarinic agonist for the treatment of Alzheimer's disease. Drug Develop Res 1997; 40: 144-57
66. Adamus WS, Leonard JP, Troger W. Phase I clinical trials with WAL 2014, a new muscarinic agonist for the treatment of Alzheimer's disease. Life Sci 1995; 56: 883-90
67. Fisher A, Brandeis R, Pittel Z, et al. (+/-)Cis-2-methyl-spiro (1,3-oxathiolane-5,3′) quinuclidine (AF102B): a new M1 agonist attenuates cognitive dysfunctions in AF64A-treated rats. Neurosci Lett 1989; 102: 325-31
68. Fisher A, Brandeis R, Karton Y, et al. Cis-2-methyl-spiro(1,3-oxathiolane-5,3′) quinuclidine an M1 selective cholinergic agonist attenuates cognitive dysfunctions in an animal model of Alzheimer's disease. J Pharmacol Exp Ther 1991; 257: 392-403
69. Fisher A, Gurwitz D, Barak D, et al. Rigid analogs of acetylcholine can be M1-selective agonists: implications for a rational treatment strategy in Alzheimer's disease. Biorg Med Chem Lett 1992; 2: 839-44
70. Fisher A, Karton Y, Heldman E, et al. Progress in medicinal chemistry of novel selective muscarinic agonists. Drug Des Discov 1993; 9: 221-35
71. Brandeis R, Sapir M, Hatif N, et al. AF150(S): a new functionally selective M1 agonist improves cognitive performance in rats. Pharmacol Biochem Behav 1995; 51: 667-74
72. Fisher A, Brandeis R, Chapman S. M1 muscarinic agonist treatment reverses cognitive and cholinergic impairments of apolipoprotein E-deficient mice. J Neurochem 1998; 70: 1991-7
73. Chapman S, Fisher A, Weinstock M, et al. The effects of the acetylcholinesterase inhibitor ENA713 and the M1 agonist AF150(S) on apolipoprotein E deficient mice. J Physiol (Paris) 1998; 92: 299-303
74. McKinney A, Anderson D, Vella-Rountree L. Different agonist-receptor active conformations for rat brain M1 and M2 muscarinic receptors that are separately coupled to two biochemical effector systems. Mol Pharmacol 1988; 35: 39-47
75. Ono S, Saito Y, Ohgane N, et al. Heterogeneity of muscarinic autoreceptors and heteroreceptors in the rat brain: effects of a novel M1 agonist, AF102B. Eur J Pharmacol 1989; 155: 77-84
76. Mochida S, Mizobe F, Fisher A, et al. Dual synaptic effects of activating M1-receptors, in superior cervical ganglia of rabbits. Brain Res 1988; 455 (1): 9-17
77. Mattson MP, Barger SW, Cheng B, et al. β-Amyloid precursor protein metabolites and loss of neuronal Ca2+ homeostasis in Alzheimer's disease. TINS 1993; 16: 409-14
78. Nitsch RM. Muscarinic receptors regulate amyloid precursor protein processing. In: Fisher A, editor. Muscarinic agonists and Alzheimer's Disease, Austin (TX): RG Landes Company, Medical Intelligence Unit, 1996: 45-54
79. Muller DM, Mendla K, Farber SA. Muscarinic M1 receptor agonists increase the secretion of the amyloid precursor protein ecrodomain. Life Sci 1997; 60: 985-91
80. Gray C, Hawkins J, Clark MSG, et al. SB 202026: a functionally M1 selective partial agonist alters processing of amyloid precursor protein at the cell surface [abstract]. Neurobiol Aging 1996; 17 Suppl.: 118
81. Pittel Z, Heldman E, Barg J, et al. Muscarinic control of amyloid precursor protein secretion in rat cerebral cortex and cerebellum. Brain Res 1996: 742: 299-304
82. Fisher A, Brandeis R, Haring R, et al. Novel M1 muscarinic agonists in treatment and delaying the progression of Alzheimer's disease: a unifying hypothesis. J Physiol (Paris) 1998; 92: 337-40
83. Farber SA, Nitsch RM, Schulz JG, et al. Regulated secretion of β-amyloid precursor protein in rat brain. J Neurosci 1995; 15: 7442-51
84. Growdon JH. Muscarinic agonists in Alzheimer's disease. Life Sci 1997: 60: 993-8
85. Lee VM-Y, Balin BJ, Otvos L, et al. A68: a major subunit of paired helical filaments and derivatized forms of normal tau. Science 1991: 251: 675-8
86. Gordon I, Grauer E, Genis I, et al. Memory deficits and cholinergic impairments in apolipoprotein E-deficient mice. Neurosci Lett 1995; 199: 1-4
87. Nakahara N, Iga Y, Mizobe F, et al. Amelioration of experimental amnesia (passive avoidance failure) in rodents by the selective M1 agonist AF102B. Jpn J Pharmacol 1988; 48: 502-6
88. Nakahara N, Iga Y, Saito Y, et al. Beneficial effects of FKS-508 (AP102B) a selective M1 muscarinic agonist, on the impaired working memory in AF64A-treated rats. Jpn J Pharmacol 1989; 51: 539-47
89. Brandeis R, Dachir S, Sapir M, et al. Reversal of age-related cognitive impairments by an M1 cholinergic agonist - AF102B. Pharmacol Biochem Behav 1990; 36: 89-95
90. O'Neil J, Fitten LJ, Siembieda D, et al. Effects of AF102B and tacrine on delayed match-to-sample in monkeys. Prog Neuropsychopharmacol Biol Psychiatry 1998, 22: 665-78
91. Vincent GP, Sepinwall J. AF102B, a novel M1 agonist, enhanced spatial learning in C57BL/10 mice with a long duration of action. Brain Res 1992; 597: 264-8
92. Roses AD. Apolipoprotein E affects the rate of Alzheimer disease expression: beta-amyloid burden is of secondary consequence dependent on APOE genotype and duration of disease. J Neuropathol Exp Neurol 1994; 53: 429-37
93. Poirier J. Delisle MC, Quirion R, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci U S A 1995; 92 (26): 12260-4
94. Davis KL, Hollander, E. Davidson M, et al. Induction of depression with oxotremorine in patients with Alzheimer's disease. Am J Psychiatry 1987; 144: 468-71
95. Spiegel R. Cholinergic drugs, affective disorders and dementia: problems of clinical research. Acta Psychiatr Scand 1991; 366 Suppl.: 66-9
96. Penn RD, Martin EM, Wilson RS, et al. Intraventricular beth anechol infusion for Alzheimer's disease. Neurology 1988; 38: 219-22
97. Sonerant TT, Raffaele KC, Asthana S, et al. Memory improvement without toxicity during chronic, low dose intravenous arecoline in Alzheimer's disease. Psychopharmacol 1993; 112: 421-7
98. Sramek JJ, Cutler NR, Hurley DJ, et al. The utility of salivary amylase as an evaluation of M3 muscarinic agonist activity in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 1995; 19: 85-91
99. 11C]butylthio-TZTP in monkey and man. Dementia 1996; 7: 187-95
100. Delong AF, Bonate PL, Gillespie T, et al. Absorption distribution, metabolism and elimination of radiolabeled xanomeline in healthy male subjects. In: Hanin I, Yoshida M, Fisher A, editors. Alzheimer's and Parkinson diseases: recent developments. New York (NY): Plenum Press, 1995: 463-8
101. Bodick NC, Offen WW, Levey AI, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 1997; 54: 465-73
102. Lilly to develop Alzheimer's patch. SCRIP 1996; 2144: 22 [online]. Available from: URL: http://www.alzforum.org/members/research/drugs/xanomeline.html [Accessed 1999 Jun 20]
103. Medina A, Bodick N, Goldberger AL, et al. Effects of central muscarinic-1 receptor stimulation on blood pressure regulation. Hypertension 1997; 29: 828-34
104. Marketletter. April 27, 1998; Alzheimer Research Forum [online]. Available from: URL: http://www.alzforum.org/members/research/drugs/memric.html [Accessed 1999 Jun 20]
105. Hoover T, Breslin E, Bridging study in the clinical development of milameline (CI-979/RU 35926), a novel muscarinic agonist [abstract]. Neurobiol Aging 1996; Suppl. 17: S139
106. Alzheimer Research Forum [online]. Available from: URL: alzforum.org/members/research/drugs/milameline.html [Accessed 1999 Jun 20]
107. Davis RE, Doyle PD, Carroll RT, et al. Cholinergic therapies for Alzheimer's disease. Palliative or disease altering? Arncimittelforschung 1995; 45: 425-31
108. Sramek JJ, Sedman AJ, Reece PA, et al. Safety and tolerability of CI-979 in patients with Alzheimer's disease. Life Sci 1995; 57: 503-10
109. Dethloff LA, Chang T, Courtney CL. Toxicological comparison of a muscarinic agonist given to rats by gavage or in the diet. Food Chem Toxicol 1996; 34: 407-22
110. Alzheimer's disease drug status update. ID Research Alerts 1997; 2 (8): 383-91
111. Sramek JJ, Hurley DJ, Wardle TS, et al. The safety and tolerance of xanomeline tartrate in patients with Alzheimer's disease. J Clin Pharmacol 1995; 35: 800-6
112. Jope RS. Cholinergic muscarinic receptor signalling by phosphoinositides signal transduction system in Alzheimer's disease. Alzheimer's Dis Rev 1996; 1: 2-14
113. Yan GM, Lin SZ, Irwin RP, et al. Activation of muscarinic cholinergic receptors blocks apoptosis of cultured cerebellar granule neurons. Mol Pharmacol 1996; 47: 257
114. Hellweg R, von Richthofen S, Anders D, et al. The time course of nerve growth factor content in different neuropsychiatric disease - a unifying hypothesis. J Neural Transm 1988; 105: 871-903
115. Nordberg A. Amberla K, Shigeta M. Long term tacrine treatment in three mild Alzheimer patients: effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG, and cognitive abilities. Alzheimer Dis Assoc Disord 1998; 12: 228-37
116. Perry E, Court J, Goodchild R, et al. Clinical neurochemistry: developments in dementia research based on brain bank material. J Neural Transm 1998; 105: 915-33
117. Lander CJ, Celesia GG, Magnuson DJ, et al. Regional alterations in M1 muscarinic receptor-G protein coupling in Alzheimer's disease. J Neuropath Exp Neurol 1995; 54: 783-9
118. Kelly JF, Furukawa K, Barger SW, et al. Amyloid β-peptide disrupts carbachol-induced muscarinic cholinergic signal transduction in cortical neurons. Proc Natl Acad Sci 1996; 96: 6753-8
119. Jope RS, Song L, Powers RE. Cholinergic activation of phosphoinositide signalling is impaired in Alzheimer's disease brain. Neurobiol Aging 1997; 18: 111-20
120. Ferrari-DiLeo G, Mash DC, Flynn DD. Attenuation of muscarinic receptor-G-protein interaction in Alzheimer disease. Mol Chem Neuropathol 1995; 24: 69-91
121. Hoshi M, Takashima A, Murayama M, et al. Nontoxic amyloid β peptide 1-42 suppresses acetylcholine synthesis. J Biol Chem 1997; 272: 2038-41
122. Abe E, Casamenti F, Giovannelli L, et al. Administration of amyloid beta-peptides into the medial septum of rats decreases acetylcholine release from hippocampus in vivo. Brain Res 1994; 636: 162-4
123. Walter J, Grunberg J, Capell A, et al. Proteolytic processing of the Alzheimer disease-associated presenilin-1 generates an in vivo substrate for protein kinase C. Proc Natl Acad Sci U S A 1997; 94: 5349-54